Induction of strong and durable cellular and humoral immunity against HIV using DNA-LNPs

Summary

Develop an HIV vaccination strategy using DNA-LNP technology to induce strong and durable cellular and humoral immunity, providing long-term protection against HIV.

What they want

The project aims to develop a novel HIV vaccination strategy by assessing the immunogenicity and durability of DNA-LNP vaccines and optimizing envelope immunogens. This includes comparing three DNA-LNP vaccines and selecting one based on immunogenicity and durability of humoral and cellular immunity. The efficacy of the optimized DNA-LNP vaccine will then be determined for protection against intravaginal tier 2 SHIV challenges in non-human primates (rhesus macaques).

Deliverables

Optimized DNA-LNP vaccine
Data on immunogenicity and durability of DNA-LNP vaccines
Data on efficacy of optimized DNA-LNP vaccine against SHIV challenges
A novel HIV vaccination strategy

Technical requirements

DNA-LNP technology
mRNA-LNP technology (for comparison)
Native-like trimeric HIV envelope (Env) gp140 immunogens (SOSIP, NFL, UFO)
Studies in rhesus macaques (RMs)
Intravaginal tier 2 SHIV challenges

Market context

inferred from NAICS

Professional, Scientific & Technical Services

NAICS 541714

US market size: $2.0T
Typical award: $25K – $50M

Typical buyers

All federal civilianDoDStates

Commonly required

8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.